Antiproliferative Activity of Buddleja saligna (Willd.) against Melanoma and In Vivo Modulation of Angiogenesis

0566373 - ÚEB 2023 RIV CH eng J - Článek v odborném periodiku
Twilley, D. - Thipe, V. C. - Kishore, N. - Bloebaum, P. - Roma-Rodrigues, C. - Baptista, J. P. V. - Fernandes, A. R. - Selepe, M. A. - Langhansová, Lenka - Katti, K. - Lall, N.
Antiproliferative Activity of Buddleja saligna (Willd.) against Melanoma and In Vivo Modulation of Angiogenesis.
Pharmaceuticals. Roč. 15, č. 12 (2022), č. článku 1497. E-ISSN 1424-8247
Institucionální podpora: RVO:61389030
Klíčová slova: angiogenesis * antiproliferative activity * Buddleja saligna * ex ovo YSM * melanoma
Obor OECD: Medicinal chemistry
Impakt faktor: 4.6, rok: 2022
Způsob publikování: Open access
https://doi.org/10.3390/ph15121497

Melanoma cells secrete pro-angiogenic factors, which stimulates growth, proliferation and metastasis, and therefore are key therapeutic targets. Buddleja saligna (BS), and an isolated triterpenoid mixture (DT-BS-01) showed a fifty percent inhibitory concentration (IC50) of 33.80 ± 1.02 and 5.45 ± 0.19 µg/mL, respectively, against melanoma cells (UCT-MEL-1) with selectivity index (SI) values of 1.64 and 5.06 compared to keratinocytes (HaCat). Cyclooxygenase-2 (COX-2) inhibition was observed with IC50 values of 35.06 ± 2.96 (BS) and 26.40 ± 4.19 µg/mL (DT-BS-01). BS (30 µg/mL) significantly inhibited interleukin (IL)-6 (83.26 ± 17.60%) and IL-8 (100 ± 0.2%) production, whereas DT-BS-01 (5 µg/mL) showed 51.07 ± 2.83 (IL-6) and 0 ± 6.7% (IL-8) inhibition. Significant vascular endothelial growth factor (VEGF) inhibition, by 15.84 ± 4.54 and 12.21 ± 3.48%, respectively, was observed. In the ex ovo chick embryo yolk sac membrane assay (YSM), BS (15 µg/egg) significantly reduced new blood vessel formation, with 53.34 ± 11.64% newly formed vessels. Silver and palladium BS nanoparticles displayed noteworthy SI values. This is the first report on the significant anti-angiogenic activity of BS and DT-BS-01 and should be considered for preclinical trials as there are currently no US Food and Drug Administration (FDA) approved drugs to inhibit angiogenesis in melanoma.
Trvalý link: https://hdl.handle.net/11104/0337711